Who founded Haya Therapeutics?

Haya Therapeutics was founded by Samir Ounzain, Daniel Blessing.

Who are Haya Therapeutics's investors?

Haya Therapeutics's investors include Broadview Ventures, Sofinnova Partners, Apollo Health Ventures, +ND Capital, 4see Ventures.

Haya Therapeutics

5 known investors

Find your way into Haya Therapeutics

68 people in our graph share verified history with the Haya Therapeutics team — schools, employers, funds. One of them is your warm intro.

Martina Paceunlockedknows Samir Ounzain · together at University of Leeds (overlapped)

×5knows the team · via Haya Therapeutics

×3knows the team · via University College London

×2knows the team · via University of Leeds

knows the team · via CHUV | Lausanne university hospital

HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

Samir Ounzain inChief Executive Officer (CEO) & Co-founderSamir Ounzain is Co-founder and CEO of Haya Therapeutics, a clinical-stage biotech company developing RNA-based therapies targeting long non-coding RNAs to treat fibrosis and cardiorenal disease.

Daniel BlessinginChief Scientific Officer (CSO) & Co-founder

Richard Lawin 𝕏Chief Business Officer (CBO)

Eric AdaminChief Operating Officer (COO)

Jordan ShininChief Medical Officer (CMO)

Jérôme AndriesinChief Financial Officer (CFO)

Investors · 5

Broadview Ventures✓ verifiedBoston

Sofinnova Partners✓ verifiedParis · $540K – $27M

Apollo Health Ventures✓ verifiedBerlin

+ND CapitalWoodside · $540K – $5.4M

4see VenturesChêne-Bougeries · $432K – $1.1Mvia Daniel Bertholet · inferred

Founder mafia

4 people who came through Haya Therapeutics went on to found or lead other companies.

Sudhir AgrawalMember, Scientific Advisory BoardFounded Aldebaran Therapeutics Dr. Jens EcksteinMember Board Of Directors, Interim ChairmanFounded Palleon Pharmaceuticals Brian ThomasExecutive and Chairman of the BoardFounded Metagenomi Denis DryginSVP DevelopmentFounded Pimera

In the news

How Haya Therapeutics is targeting the dark genome to treat fibrotic diseasecen.acs.org · Jun 2026

Frequently asked questions

What does Haya Therapeutics do?: HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
Who founded Haya Therapeutics?: Haya Therapeutics was founded by Samir Ounzain, Daniel Blessing.
Who are Haya Therapeutics's investors?: Haya Therapeutics's investors include Broadview Ventures, Sofinnova Partners, Apollo Health Ventures, +ND Capital, 4see Ventures.